Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
Original title: “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide”
The randomized Phase II trial will ... the on-trial multi-omic analyses will investigate cellular mechanisms that could guide personalized and precision-based approaches. The research may also identify potential biomarkers and combinatorial strategies for future interventions, with the potential to advance the treatment paradigm for GERD and inform future clinical development.” · N-Zyme is developing fosamprenavir as a novel therapeutic approach to reflux disease based on ... The randomized Phase II trial will provide important data on the efficacy of fosamprenavir, while the on-trial multi-omic analyses will investigate cellular mechanisms that could guide personalized and precision-based approaches. The research may also identify potential biomarkers and combinatorial strategies for future interventions, with the potential to advance the treatment paradigm for GERD and inform future clinical development.” · N-Zyme is developing fosamprenavir as a novel therapeutic approach to reflux disease based on inhibition of pepsin, a digestive enzyme increasingly implicated in reflux-related tissue injury. NIH-supported research will evaluate the mechanistic effects of fosamprenavir and support a Phase II randomized, double-blind, placebo-controlled clinical trial in patients with PPI-refractory GERD · WAUWATOSA, Wis. & NEWARK, Del.--(BUSINESS WIRE)--#Award--N-Zyme Biomedical Inc. (“N-Zyme”), a clinical-stage biotechnology company developing novel pepsin-targeted therapies for reflux disease, today announced that a research team led by N-Zyme Co-Founder and Chief Scientific Officer Dr. Unlike conventional therapies focused primarily on suppressing gastric acid, N-Zyme’s approach is designed to target pepsin-mediated injury as a distinct component of reflux disease. N-Zyme will serve as the sponsor of the Phase II clinical trial. Nikki Johnston has been awarded US$2.76 million through an R01 research grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to advance the study of fosamprenavir in proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). The award, administered through the Medical College of Wisconsin (MCW), will support an integrated translational and clinical research program evaluating fosamprenavir, N-Zyme’s lead drug candidate, as a potential treatment for patients with GERD whose symptoms persist despite PPI therapy.
Original title: “N-Zyme Biomedical Program Receives US$2.76 Million NIH Award to Advance Fosamprenavir for PPI-Refractory GERD - BioSpace”
Novo CEO Maziar Mike Doustdar disclosed an additional 4,000 staff departures, which a spokesperson told BioSpace are linked to attrition and other measures.
Original title: “Novo’s workforce reduction climbs to 13,000 to fuel R&D work”
Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates and T cell engagers.
Original title: “Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics”
Deal strengthens company’s established medicines strategy
Original title: “Grünenthal acquires cancer medicine Stivarga”
Regulator supports earlier multiple myeloma treatment option
Original title: “CHMP backs expanded use of teclistamab”
As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
Original title: “Deep Dive: How AI is now essential in biopharma”
cross ethnic replication of intersectin 1 as a parkinson s disease susceptibility gene in a large chinese cohort
Original title: “Cross-Ethnic Replication of Intersectin-1 as a Parkinson's Disease Susceptibility Gene in a Large Chinese Cohort.”